Sanofi bolsters its position on multiple sclerosis with a $765M BTK licensing deal
Sanofi is snapping up an early-stage program from San Francisco’s Principia Biopharma, shoring up the pharma giant’s position in multiple sclerosis.
Sanofi will write a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
